Pharmacogenomics Company OneOme Announces Leadership Promotions

MINNEAPOLIS (Jan. 26, 2017) – Pharmacogenomics company OneOme announced today that Jason Ross will serve as its chief technology officer and that Josiah Allen was promoted to OneOme’s director of medical affairs.

“We are glad to add Josiah Allen and Jason Ross to our leadership team,” said Paul Owen, CEO of OneOme. “OneOme is on the cutting edge of making prescriptions personal, and Josiah and Jason bring the medical and technological expertise to make that dream a reality.”

Jason Ross earned a master’s degree in health and human services administration from St. Mary’s University and has a bachelor’s degree in molecular biology from the University of Wisconsin-Eau Claire. Ross previously served as senior director of implementation at OneOme and oversaw the integration of OneOme’s RightMed pharmacogenomic test to customers’ Electronic Medical Record (EMR) solutions. Ross has substantial experience in management and leadership in healthcare information technology, including numerous leadership positions at Mayo Clinic. His research experience spans both clinical and research domains. As chief technology officer, Ross will ensure OneOme’s technology is providing cutting edge solutions to its customers.

As director of medical affairs for OneOme, Josiah Allen will lead a team of medical and scientific professionals to facilitate education and awareness of pharmacogenomics among providers, thought leaders, and other keystake holders. Allen earned his bachelor’s degree from Wheaton College in Illinois and completed post-graduate coursework in organic chemistry and molecular genetics at the University of Cincinnati. Allen has co-authored a number of scientific studies on pharmacogenomics and its clinical impacts. He previously worked at the Mayo Clinic Center for Individualized Medicine and led medical information and scientific development at Assurex Health.

The leadership moves are the latest announcement from OneOme, which continues to grow as a leading pharmacogenomics company. Last week OneOme announced that is has gained laboratory certification in five states. OneOme also gained a “Patent Pending” status from the U.S. Patent and Trademark office status for its RightMed pharmacogenomic test and its online tool, RightMed Advisor.

The OneOme platform brings pharmacogenomics into routine clinical care. By using a physician-ordered cheek swab test taken at home or as part of a doctor’s visit, physicians will have a better idea of how their patients’ 22 genes analyzed through the test will respond to various medications.

OneOme’s RightMed test was developed to offer a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes provided as part of routine clinical care. The test helps providers easily make personalized treatment decisions across more than 340 medications. OneOme also has developed a platform aimed at institutions who want a physician friendly interpretive drug report generated using genotype or sequence data obtained in a non-OneOme laboratory, all with the goal of better identifying which prescription medications may work best for individual patients.

Anyone can take the RightMed test; some patients who may benefit most include: those who are taking some classes of medication, such as cardiovascular or psychiatric patients; those who are struggling with adverse drug reactions and/or medications that are not working; and/or those who are on multiple medications.

While the RightMed test is available globally, OneOme has formal partnerships with High Profile Laboratory in Guaynabo, Puerto Rico, to serve Puerto Rico, Cuba, and the Dominican Republic. The company also operates in partnership with Medcan, Canada’s largest executive health clinic, and recently announced the additions of Minnesota-based Ridgeview Medical Center and Centra Health’s Stroobants Cardiovascular Center in Central Virginia to its provider network.

About OneOme
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit